猴痘疫苗和治療藥物全球市場規模、佔有率、趨勢和成長分析報告（2026-2034年）

預計猴痘疫苗和治療藥物市場將從 2025 年的 1.2147 億美元成長到 2034 年的 3.0423 億美元，2026 年至 2034 年的複合年成長率為 10.74%。

由於全球猴痘感染疾病不斷爆發，猴痘疫苗和治療藥物的全球市場備受關注。多國疫情凸顯了有效疫苗和抗病毒治療方法的迫切需求。隨著各國政府和醫療機構致力於控制疫情蔓延，對預防性疫苗和治療藥物的需求也穩定成長。

製藥公司和研究機構正大力投資疫苗研發和抗病毒療法，以對抗疾病。現有的疫苗最初是為預防天花而研發的，已被證明對猴痘有效，同時人們也在尋求新的治療方法來改善疾病管理。公共衛生措施和政府採購計畫也在支持市場擴張。

隨著全球對新興感染疾病的監測和預防力度不斷加強，猴痘疫苗和治療市場預計將會成長。公眾意識的提高、診斷能力的提升以及對新一代疫苗的持續研發都將促進市場發展。各國政府、醫療機構和製藥公司之間的持續合作將在塑造市場未來方面發揮關鍵作用。

目錄

第1章：引言

第2章執行摘要

第3章 市場變數、趨勢與框架

• 市場譜系展望
• 滲透率和成長前景分析
• 價值鏈分析
• 法律規範
  • 標準與合規性
  • 監管影響分析
• 市場動態
  • 市場促進因素
  • 市場限制因素
  • 市場機遇
  • 市場挑戰
• 波特五力分析
• PESTLE分析

第4章 全球猴痘疫苗與治療市場：依產品分類

• 市場分析、洞察與預測
• 疫苗（如 Jynneos/Imvanex、天花疫苗等）
• 藥物（替可比利馬特、布林西多福韋、西多福韋等）
• 牛痘免疫球蛋白（VIG）

第5章 全球猴痘疫苗與治療市場：依性別分類

• 市場分析、洞察與預測
• 男性
• 女士
• 其他

第6章 全球猴痘疫苗與治療藥物市場：依給藥途徑分類

• 市場分析、洞察與預測
• 口服
• 注射藥物

第7章 全球猴痘疫苗和治療市場：依最終用途分類

• 市場分析、洞察與預測
• 醫院
• 專科診所
• 其他

第8章 全球猴痘疫苗和治療市場：按地區分類

• 區域分析
• 北美市場分析、洞察與預測
  • 美國
  • 加拿大
  • 墨西哥
• 歐洲市場分析、洞察與預測
  • 英國
  • 法國
  • 德國
  • 義大利
  • 俄羅斯
  • 其他歐洲國家
• 亞太市場分析、洞察與預測
  • 印度
  • 日本
  • 韓國
  • 澳洲
  • 東南亞
  • 其他亞太國家
• 拉丁美洲市場分析、洞察與預測
  • 巴西
  • 阿根廷
  • 秘魯
  • 智利
  • 其他拉丁美洲國家
• 中東和非洲市場分析、洞察與預測
  • 沙烏地阿拉伯
  • UAE
  • 以色列
  • 南非
  • 其他中東和非洲國家

第9章 競爭情勢

• 最新趨勢
• 公司分類
• 供應鏈和銷售管道合作夥伴（根據現有資訊）
• 市場佔有率和市場定位分析（基於現有資訊）
• 供應商情況（基於現有資訊）
• 策略規劃

第10章：公司簡介

• 主要公司的市佔率分析
• 公司簡介
  • Bavarian Noric
  • SIGA Technologies
  • Chimerix
  • Emergent
  • Gilead Sciences Inc

The Monkeypox Vaccine And Treatment Market size is expected to reach USD 304.23 Million in 2034 from USD 121.47 Million (2025) growing at a CAGR of 10.74% during 2026-2034.

The global monkeypox vaccine and treatment market has gained considerable attention due to the increasing incidence of monkeypox infections across various regions. The outbreak of the disease in several countries has highlighted the need for effective vaccines and antiviral treatments. As governments and healthcare organizations focus on controlling outbreaks, the demand for preventive vaccines and therapeutic drugs is increasing steadily.

Pharmaceutical companies and research institutions are investing heavily in vaccine development and antiviral therapies to address the disease. Existing vaccines originally developed for smallpox have shown effectiveness against monkeypox, while new treatments are being explored to improve disease management. Public health initiatives and government procurement programs are also supporting the expansion of the market.

In the future, the monkeypox vaccine and treatment market is expected to grow as global surveillance and preparedness for emerging infectious diseases increase. Rising awareness, improved diagnostic capabilities, and ongoing research into next-generation vaccines will contribute to market development. Continued collaboration between governments, healthcare organizations, and pharmaceutical companies will play a key role in shaping the market's future.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Product

• Vaccine (Jynneos/ Imvanex, Smallpox Vaccine, Others)
• Drugs (Tecovirimat, Brincidofovir, Cidofovir, Others)
• Vaccinia Immune Globulin (Vig)

By Gender

• Male
• Female
• Others

By Route Of Administration

• Oral
• Injectable
• By-End-Use
• Hospitals
• Specialty Clinics
• Others

COMPANIES PROFILED

• Bavarian Noric, SIGA Technologies, Chimerix, Emergent, Gilead Sciences Inc
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL MONKEYPOX VACCINE AND TREATMENT MARKET: BY PRODUCT 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Product
• 4.2. Vaccine (Jynneos/ Imvanex, Smallpox Vaccine, Others) Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Drugs (Tecovirimat, Brincidofovir, Cidofovir, Others) Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Vaccinia Immune Globulin (Vig) Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL MONKEYPOX VACCINE AND TREATMENT MARKET: BY GENDER 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Gender
• 5.2. Male Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Female Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL MONKEYPOX VACCINE AND TREATMENT MARKET: BY ROUTE OF ADMINISTRATION 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Route Of Administration
• 6.2. Oral Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Injectable Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL MONKEYPOX VACCINE AND TREATMENT MARKET: BY BY-END-USE 2022-2034 (USD MN)

• 7.1. Market Analysis, Insights and Forecast By-end-use
• 7.2. Hospitals Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.3. Specialty Clinics Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.4. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 8. GLOBAL MONKEYPOX VACCINE AND TREATMENT MARKET: BY REGION 2022-2034(USD MN)

• 8.1. Regional Outlook
• 8.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.2.1 By Product
  • 8.2.2 By Gender
  • 8.2.3 By Route Of Administration
  • 8.2.4 By By-end-use
  • 8.2.5 United States
  • 8.2.6 Canada
  • 8.2.7 Mexico
• 8.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.3.1 By Product
  • 8.3.2 By Gender
  • 8.3.3 By Route Of Administration
  • 8.3.4 By By-end-use
  • 8.3.5 United Kingdom
  • 8.3.6 France
  • 8.3.7 Germany
  • 8.3.8 Italy
  • 8.3.9 Russia
  • 8.3.10 Rest Of Europe
• 8.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.4.1 By Product
  • 8.4.2 By Gender
  • 8.4.3 By Route Of Administration
  • 8.4.4 By By-end-use
  • 8.4.5 India
  • 8.4.6 Japan
  • 8.4.7 South Korea
  • 8.4.8 Australia
  • 8.4.9 South East Asia
  • 8.4.10 Rest Of Asia Pacific
• 8.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.5.1 By Product
  • 8.5.2 By Gender
  • 8.5.3 By Route Of Administration
  • 8.5.4 By By-end-use
  • 8.5.5 Brazil
  • 8.5.6 Argentina
  • 8.5.7 Peru
  • 8.5.8 Chile
  • 8.5.9 South East Asia
  • 8.5.10 Rest of Latin America
• 8.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.6.1 By Product
  • 8.6.2 By Gender
  • 8.6.3 By Route Of Administration
  • 8.6.4 By By-end-use
  • 8.6.5 Saudi Arabia
  • 8.6.6 UAE
  • 8.6.7 Israel
  • 8.6.8 South Africa
  • 8.6.9 Rest of the Middle East And Africa

Chapter 9. COMPETITIVE LANDSCAPE

• 9.1. Recent Developments
• 9.2. Company Categorization
• 9.3. Supply Chain & Channel Partners (based on availability)
• 9.4. Market Share & Positioning Analysis (based on availability)
• 9.5. Vendor Landscape (based on availability)
• 9.6. Strategy Mapping

Chapter 10. COMPANY PROFILES OF GLOBAL MONKEYPOX VACCINE AND TREATMENT INDUSTRY

• 10.1. Top Companies Market Share Analysis
• 10.2. Company Profiles
  • 10.2.1 Bavarian Noric
  • 10.2.2 SIGA Technologies
  • 10.2.3 Chimerix
  • 10.2.4 Emergent
  • 10.2.5 Gilead Sciences Inc